Home › NDC Lookup › Ingredients › Mexiletine Hydrochloride › 00093-8739-01
Mexiletine Hydrochloride 150 mg Capsule, 100-count — NDC 00093-8739-01 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

Mexiletine Hydrochloride 150 mg Capsule, 100-count — NDC 0093-8739-01 (Billing 00093-8739-01)

by Teva Pharmaceuticals USA, Inc. · 100 CAPSULE in 1 BOTTLE

This is a package of 100 capsules of Mexiletine Hydrochloride 150 mg Capsule from Teva Pharmaceuticals USA, Inc., marketed since Mar 2023 and currently FDA-listed; retail pharmacies pay about $0.2225 per capsule (NADAC). It is the main listing for this product, which comes in 2 package sizes.

NDC 00093-8739-01
🏷️ FDA NDC (as labeled) 0093-8739-01 billing pads the labeler segment with a zero
This package
Contains100-count Cost per ea$0.2225 NADAC Per package$22.25 / 100 capsules Pack sizes2 compare ↓
Also priced by: Medicaid pays $0.4652/unit · Part D plans $0.6000/unit — full pricing hub ↓
Main listing for product 0093-8739 · Also comes in: 62500 capsules 0093-8739-99
On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Oct 8, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 0093-8739-01 alone.

Record
FDA NDC Directory package listing · Drug for further processing
Code segments
0093 labeler · 8739 product · 01 package
Listing certified through
Dec 31, 2026
Billing quantity
100 EA per package
Barcode (UPC-A, from the NDC)
3 0093873901 1
Medicaid fills, this package
1,593 prescriptions in the last four reported quarters
FDA record last changed
Oct 8, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 0093-8739-01
Product NDC 0093-8739
11-digit billing NDC 00093873901
NCPDP billing unit EA — each (per item)
SPL Set ID c65394df-caeb-4d3d-b01c-bc30a492c9ca
DEA schedule Non-controlled
Marketing category DRUG FOR FURTHER PROCESSING
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2023-03-30
Dosage form CAPSULE
Substance MEXILETINE HYDROCHLORIDE

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 35200025100105
GPI class Mexiletine HCl
GCN Seq No 000267
GCN 12210
HICL code 000084
Ingredient (HICL) Mexiletine Hcl
HIC1 code A
Therapeutic class — broad (HIC1) Cardiovascular System
HIC2 code A2
Therapeutic class — intermediate (HIC2) Cardiac Depressants
HIC3 code A2A
Therapeutic class — specific (HIC3) Antiarrhythmics
AHFS code 24:04.04.08
AHFS class Class Ib Antiarrhythmics
FDB label name MEXILETINE 150 MG CAPSULE
FDB brand name Mexiletine Hcl
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 000267
  • GCN: 12210
  • GPI-14 (Medi-Span): 35200025100105
  • HICL (First Databank): 000084
  • AHFS class code: 24:04.04.08
Why two NDCs? The FDA registers this code as 0093-8739-01 — a 4-4-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the labeler segment → 00093-8739-01. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

Clinical

Label name MEXILETINE 150 MG CAPSULE Ingredient Mexiletine Hcl
📗 Our plain-language guide HelloPharmacist
  • It treats dangerous ventricular arrhythmias, which are abnormal fast rhythms from the lower heart chambers, like sustained ventricular tachycardia. It is not meant for milder rhyth...
  • Take it by mouth, usually about every 8 hours, with food or an antacid. That helps with stomach upset. Follow your prescriber's schedule and don't change it on your own.
  • Many people get stomach upset, dizziness, shakiness, coordination trouble or nervousness. These often ease with food or a dose change, so tell your doctor if they bother you. Don't...
  • Call if you faint, have a very slow or irregular heartbeat, or get a rash with fever or swollen glands. Also call for seizures, confusion, black stools, unusual bruising or infecti...
📖 Read our full Mexiletine guide →

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $0.223 $22.25 / 100 capsules
Medicaid paysCMS SDUD · 12 mo $0.4652 $46.52 / 100 capsules
Medicare drug plans payPart D · Q2 2026 $0.6000 $60.00 / 100 capsules
NADAC price history (per ea) — tap or hover for the price & month
Jan 2022 Aug 2022 Jan 2026 Sep 2026 $0.763 $0.223
▼ Down 64% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
00093-8739-01 You're viewing this Main listing 100 CAPSULE in 1 BOTTLE $0.2225 / ea $22.25 1995-06-05 — Active
00093-8739-99 0093-8739-99 62500 CAPSULE in 1 PAIL — — — — Active

You're viewing the smallest of 2 pack sizes for this product.

In Medicaid, this is the most-dispensed pack of this product — about 100% of fills over the last four reported quarters. See all packs ↓

Pack size FAQ

What quantity is in this package?
This is a 100-count package — 100 capsule in 1 bottle.
How does this package differ from NDC 00093-8739-99?
Both are Mexiletine Hydrochloride 150 mg Capsule — the drug itself is identical. This page's package is the 100-count one, while NDC 00093-8739-99 is the 62500 capsules package.
What NDC number is used to bill for this package of Mexiletine Hydrochloride 150 mg Capsule?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Mexiletine Hydrochloride 150 mgthis 00093-8739-01 Teva 100 capsules $0.222 — Availability likely —
Mexiletine Hydrochloride 150 mg 00527-4107-37 Lannett 100 capsules $0.222 AB Discontinued —
Mexiletine hydrochloride 150 mg 31722-0036-01 Camber 100 capsules $0.222 AB Availability likely —
Mexiletine Hydrochloride 150 mg 50742-0239-01 Ingenus 100 capsules $0.222 AB Availability likely —
Mexiletine hydrochloride 150 mg 60687-0778-21 American 30 capsules $0.222 AB Availability likely —
Mexiletine Hydrochloride 150 mg 62559-0820-01 ANI 100 capsules $0.222 AB Availability likely —
Mexiletine Hydrochloride 150 mg 62756-0955-01 Sun 100 capsules $0.222 AB Availability likely —
Mexiletine Hydrochloride 150 mg 64980-0666-01 Rising 100 capsules $0.222 AB Availability likely —
Mexiletine Hydrochloride 150 mg 33342-0555-11 Macleods 100 capsules — AB FDA listed —
Mexiletine Hydrochloride 150 mg 42291-0624-01 AvKARE 100 capsules — AB FDA listed —
Mexiletine Hydrochloride 150 mg 51407-0379-01 Golden 100 capsules — AB FDA listed —
Mexiletine Hydrochloride 150 mg 63629-2145-01 Bryant 100 capsules — AB FDA listed —
Mexiletine Hydrochloride 150 mg 63629-9179-01 Bryant 100 capsules — AB FDA listed —
Mexiletine Hydrochloride 150 mg 71335-2922-01 Bryant 100 capsules — AB FDA listed —
Mexiletine Hydrochloride 150 mg 72162-1772-01 Bryant 100 capsules — AB FDA listed —
Mexiletine Hydrochloride 150 mg 72162-1782-01 Bryant 100 capsules — AB FDA listed —
Mexiletine Hydrochloride 150 mg 82012-0027-04 Senores 100 capsules — — FDA listed —
Mexiletine Hydrochloride 150 mg 71335-3171-01 Bryant 90 capsules — AB FDA listed —
Mexiletine Hydrochloride 150 mg 87564-0052-10 Amerisyn 100 capsules — AB FDA listed —
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2023
On the market since
Mar 2023
📍
2026
Currently FDA-listed
3 years listed
🔓
·
Generic versions listed
see equivalents
✅Generic appears available

FDA-approved generic versions are listed, and recent pricing/market data suggests they may be available — see Therapeutic equivalents.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

What it looks like

Color orange / brown / green
ShapeCapsule
ImprintN;741;250
Size22 mm
ScoringNot scored
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

🧪 Avoiding an ingredient? See Mexiletine inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII 3K9958V90M
    A liquid solvent derived from fermentation or chemical synthesis. In medicines, alcohol dissolves active ingredients, helps preserve the product, and improves how the body absorbs certain drugs.
  • UNII 5138Q19F1X
    Ammonia is a colorless gas made from nitrogen and hydrogen. It's used in medicines as a pH buffer to maintain the correct acidity level and help keep the product stable.
  • UNII 8PJ61P6TS3
    Butyl alcohol is a clear liquid organic solvent derived from petroleum or natural sources. In medicines, it helps dissolve active ingredients and serves as a solvent in liquid formulations and some topical products.
  • UNII 767IP0Y5NH
    A synthetic red colorant used to give medicines their color. It helps patients identify their medication and makes the product visually appealing.
  • UNII 35SW5USQ3G
    A synthetic yellow dye used to color medicines. It helps make tablets, capsules, and liquids visually distinct so patients can easily identify their medication.
  • UNII H3R47K3TBD
    FD&C Blue No. 1 is a synthetic blue dye approved for use in foods and medicines. It serves as a colorant to give the medication its distinctive appearance and help with product identification.
  • UNII L06K8R7DQK
    A synthetic blue dye approved by the FDA for use in medications and foods. It serves as a colorant to make pills and liquids visually distinct and easier to identify.
  • UNII WZB9127XOA
    A synthetic red dye used to color medications and make them easier to identify. It serves as a colorant in tablets, capsules, and liquid formulations.
  • UNII H77VEI93A8
    A synthetic yellow dye used to color medications. It helps identify the drug and make it visually distinctive, with no effect on how the medicine works.
  • UNII XM0M87F357
    A dark iron oxide compound that gives medicines their black or dark color. It's used as a colorant in tablets and capsules to help identify the product and make it visually distinctive.
  • UNII 2G86QN327L
    Gelatin is a protein derived from animal collagen, commonly used in medicines as a gelling agent and capsule material. It helps create soft or hard capsule shells that hold and release medication, and can also thicken liquid formulations.
  • UNII ND2M416302
    Isopropyl alcohol is a clear liquid solvent derived from petroleum. In medicines, it dissolves active ingredients and other components, helps the product flow smoothly, and aids in sterilization during manufacturing.
  • UNII 70097M6I30
    Magnesium stearate is a salt made from magnesium and stearic acid, a fatty substance. It's used in tablets and capsules as a lubricant and glidant to help ingredients flow smoothly during manufacturing and prevent sticking.
  • UNII 6DC9Q167V3
    Propylene glycol is a clear liquid derived from petroleum or vegetable sources. It acts as a solvent, humectant, and preservative in medicines, helping dissolve active ingredients and maintain product stability.
  • UNII 46N107B71O
    Shellac is a natural resin secreted by the lac beetle. It's used as a coating on tablets and capsules to control how quickly the medicine dissolves and to improve appearance and stability.
  • UNII ETJ7Z6XBU4
    Silicon dioxide is a naturally occurring mineral used as a glidant and anti-caking agent. It helps powder ingredients flow smoothly and prevents clumping during manufacturing and storage.
  • UNII O8232NY3SJ
    A plant-based carbohydrate derived from corn kernels. It acts as a filler to add bulk, a binder to hold ingredients together, and a disintegrant to help the tablet break apart in your stomach for absorption.
  • UNII 15FIX9V2JP
    Titanium dioxide is a bright white mineral powder commonly used as a colorant and opacifying agent. It makes pills and tablets white or lighter in color and helps make coatings non-transparent.

18 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerTeva Pharmaceuticals USA, Inc.
Labeler code00093
First marketedMar 2023
Product typeDrug For Further Processing
Portfolio504 products on file

More NDCs from Teva Pharmaceuticals USA, Inc. labeler code 00093

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full FDA label FDA SPL

The complete FDA label for this product, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
📄 FDA label
📄 FDA label 19 words ▾

No FDA label is on file for this product yet. Labels load from openFDA / DailyMed and refresh weekly.

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q4 2025 · 4 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
1.6K
Units reimbursed last 4 qtrs
172.5K
Gross reimbursed last 4 qtrs
$80.2K
Avg / prescription
$50.36
Avg / unit
$0.4652
Latest quarter Q4 2025
368Rx
Medicaid pays / ea
$0.4652
gross reimbursed
vs
NADAC / ea
$0.2225
acquisition cost
=
Spread
+$0.2427
+109% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
45% FFS 55% MCO
Fee-for-service · 718 Rx Managed care · 875 Rx
State Medicaid map
Alaska: 780 units · 106 per 100k residents AK Maine: no data reported ME Washington: 1,494 units · 19.1 per 100k residents WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: no data reported MN Wisconsin: no data reported WI Michigan: no data reported MI New York: 13,815 units · 70.6 per 100k residents NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: no data reported OR Nevada: no data reported NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: no data reported IL Indiana: no data reported IN Ohio: no data reported OH Pennsylvania: 3,980 units · 30.7 per 100k residents PA New Jersey: 2,556 units · 27.5 per 100k residents NJ Massachusetts: 17,249 units · 246 per 100k residents MA California: 46,058 units · 118 per 100k residents CA Utah: no data reported UT Colorado: no data reported CO Nebraska: no data reported NE Missouri: no data reported MO Kentucky: no data reported KY West Virginia: no data reported WV Virginia: 8,210 units · 94.2 per 100k residents VA Maryland: 3,020 units · 48.9 per 100k residents MD Connecticut: 10,695 units · 296 per 100k residents CT Rhode Island: no data reported RI Arizona: no data reported AZ New Mexico: no data reported NM Kansas: no data reported KS Arkansas: no data reported AR Tennessee: 1,881 units · 26.4 per 100k residents TN North Carolina: 15,270 units · 141 per 100k residents NC South Carolina: 5,758 units · 107 per 100k residents SC Delaware: no data reported DE Oklahoma: no data reported OK Louisiana: no data reported LA Mississippi: no data reported MS Alabama: no data reported AL Georgia: 6,999 units · 63.5 per 100k residents GA D.C.: no data reported DC Hawaii: no data reported HI Texas: 9,812 units · 32.2 per 100k residents TX Florida: 24,893 units · 110 per 100k residents FL
Units reimbursed · per 100k residents
19.1296
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Connecticut 296 /100k
2 Massachusetts 246 /100k
3 North Carolina 141 /100k
4 California 118 /100k
5 Florida 110 /100k
6 South Carolina 107 /100k
7 Alaska 106 /100k
8 Virginia 94.2 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
100 capsules this page00093-8739-01 1,637 Rx · $82,379
62500 capsules00093-8739-99 No Medicaid data
Drug total (last 4 qtrs): 1,637 Rx · 180,039 units · $82,379 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

About this NDC listing & data coverage

Listed for further processing / repackaging

What "drug for further processing" means

FDA lists this package under the "drug for further processing" marketing category: Teva Pharmaceuticals USA, Inc. supplies it to other companies for further processing or repackaging (blister cards that are later repackaged or co-packaged are a common example). The units themselves are a finished dosage form — which is why pricing or Medicaid data can still appear — but this exact package code may not be the presentation a retail pharmacy dispenses.

What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos ✓ Available
Inactive ingredients (structured) ✓ Available
NADAC pharmacy acquisition price (CMS) ✓ Available
Orange Book / therapeutic-equivalence data — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope.
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) ✓ Available
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Is this NDC FDA-approved?
An NDC listing does not by itself establish FDA approval — the NDC Directory records that a product is listed with FDA, not that it was reviewed and approved. This listing's marketing category is "Drug For Further Processing". Products approved under an application carry an NDA, ANDA, or BLA number.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by Teva Pharmaceuticals USA, Inc.. Listing status can change — the directory data on this page refreshes weekly.
Does this product come in other package sizes?
Yes — the FDA directory lists 1 other package presentation of this same product, including 62500 capsules (00093-8739-99). Each has its own NDC and its own page — see the package list near the top of this page.
Who lists this product with the FDA?
Teva Pharmaceuticals USA, Inc. is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
← 00093-8675-74 · Teva 00093-8740-01 · Teva →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.